| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2008.17.7840 |
| P698 | PubMed publication ID | 19001323 |
| P50 | author | Constantin T Yiannoutsos | Q83393956 |
| P2093 | author name string | Thomas Anderson | |
| Cynthia Johnson | |||
| Angela White | |||
| Ramaswamy Govindan | |||
| Lawrence Einhorn | |||
| Nasser Hanna | |||
| Rafat Ansari | |||
| Donald Richards | |||
| William Fisher | |||
| Marcus Neubauer | |||
| Sreenivasa Nattam | |||
| Craig Reynolds | |||
| Daniel Bruetman | |||
| Tim Breen | |||
| James Arseneau | |||
| Anton Melnyk | |||
| Hoosier Oncology Group | |||
| Naveed Chowhan | |||
| Prasad Mantravadi | |||
| Ronald McGarry | |||
| US Oncology | |||
| P433 | issue | 35 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| patient | Q181600 | ||
| cisplatin | Q412415 | ||
| etoposide | Q418817 | ||
| docetaxel | Q420436 | ||
| P304 | page(s) | 5755-5760 | |
| P577 | publication date | 2008-11-10 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology | |
| P478 | volume | 26 |
| Q27002509 | 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer |
| Q27014978 | 50 Years of progress in the systemic therapy of non-small cell lung cancer |
| Q41990323 | A Bystander Effect of Lung Cancer Chemotherapy on Chronic Echinococcal Disease |
| Q82429731 | A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer |
| Q35999362 | A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer |
| Q35836792 | A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533 |
| Q92067247 | A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer |
| Q97649635 | A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179 |
| Q34041735 | A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer |
| Q37728090 | A phase I study of temsirolimus and thoracic radiation in non--small-cell lung cancer |
| Q35996196 | A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI). |
| Q33407408 | A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer |
| Q35134354 | A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer |
| Q45923193 | A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study. |
| Q40155605 | A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer |
| Q35854707 | A single-nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy |
| Q34466023 | CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma |
| Q61583102 | Cancers bronchiques non à petites cellules localement avancés : quelle radiothérapie en 2014 ? |
| Q36989648 | Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer |
| Q37614566 | Chemotherapy for lung cancer: the state of the art in 2009. |
| Q84582198 | Chemotherapy in stage III non-small cell lung cancer |
| Q30871677 | Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data |
| Q37395888 | Cisplatin versus carboplatin in NSCLC: is there one "best" answer? |
| Q34771247 | Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer |
| Q91844914 | Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer |
| Q36993644 | Combined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations |
| Q47126832 | Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505). |
| Q53216825 | Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients. |
| Q35397008 | Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy |
| Q33412557 | Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. |
| Q40339097 | Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study |
| Q34493493 | Concurrent chemoradiotherapy with tomotherapy in locally advanced Non-Small Cell Lung Cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen |
| Q35167387 | Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience |
| Q34672375 | Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer |
| Q26851579 | Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature |
| Q35810871 | Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy--retrospective analysis of 203 cases |
| Q37108127 | Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis |
| Q38884025 | Continuous Activity Monitoring During Concurrent Chemoradiotherapy. |
| Q38176433 | Controversies in the management of stage III non-small-cell lung cancer |
| Q89710930 | Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab |
| Q39139831 | Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis |
| Q38549486 | Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line? |
| Q55079845 | Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer. |
| Q55304879 | Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. |
| Q37180302 | EGFR inhibition in non-small cell lung cancer: current evidence and future directions |
| Q37538757 | EGFR-directed therapies to treat non-small-cell lung cancer |
| Q47132869 | Early PET/CT scans for assessing treatment responses of non-small cell lung cancer for SBRT boost: what to do with scans from multiple scanners |
| Q45794075 | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q91606046 | Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial |
| Q89572724 | Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies |
| Q40951849 | GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer |
| Q34093083 | Going past the data for temozolomide |
| Q44070976 | Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group |
| Q89017230 | How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience |
| Q57022957 | Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database |
| Q89884254 | Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives |
| Q56891772 | Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer |
| Q26738359 | Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment |
| Q55322253 | Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care? |
| Q64998544 | Immunotherapy in inoperable stage III non-small cell lung cancer: a review. |
| Q54978827 | Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages? |
| Q99589745 | Impacts of post-radiotherapy lymphocyte count on progression-free and overall survival in patients with stage III lung cancer |
| Q36776988 | Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy |
| Q30382413 | Improving survival of patients with locally advanced non-small-cell cancer remains a challenge: comment to PROCLAIM. |
| Q55529918 | Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis. |
| Q53455433 | Induction Chemotherapy and Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Patients With Locally Advanced Inoperable Non–Small-Cell Lung Cancer: The MRC INCH Randomized Trial |
| Q37977438 | Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine |
| Q38771934 | Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. |
| Q89116529 | Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer? |
| Q34430511 | L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review |
| Q38558894 | Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration |
| Q90100983 | Locally Advanced, Unresectable Non-Small Cell Lung Cancer |
| Q44957834 | Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer |
| Q46049056 | Lung cancer: New biological insights and recent therapeutic advances |
| Q37798621 | Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer |
| Q27011282 | Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea |
| Q82577460 | Medical oncology: Chemoradiotherapy for NSCLC-does a 'standard' exist? |
| Q37921958 | Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions. |
| Q33583931 | Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision |
| Q38930358 | Multimodality Therapy for NSCLC. |
| Q38689410 | New Model for Estimating Glomerular Filtration Rate in Patients With Cancer |
| Q38387311 | Nivolumab: targeting PD-1 to bolster antitumor immunity |
| Q85178117 | Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ≥ 80 Gy in standard fractionation |
| Q51021428 | Non-small-cell lung cancer. |
| Q26827571 | Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer |
| Q47204412 | Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC. |
| Q35147409 | Opportunistic illnesses in Brazilian children with AIDS: results from two national cohort studies, 1983-2007. |
| Q35584972 | Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. |
| Q40098978 | Outcomes of chemoradiation for patients with locally advanced non-small-cell lung cancer. |
| Q38682031 | Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer |
| Q90636850 | Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study |
| Q37799826 | Personalized medicine for non-small-cell lung cancer. |
| Q64256380 | Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer |
| Q52682575 | Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). |
| Q33410020 | Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer |
| Q55284746 | Phase I study of concurrent and consolidation cisplatin and docetaxel chemotherapy with thoracic radiotherapy in non-small cell lung cancer. |
| Q40079747 | Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer. |
| Q33414911 | Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer |
| Q54685400 | Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401. |
| Q37339650 | Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer |
| Q37227687 | Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial |
| Q40660706 | Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis |
| Q35874455 | Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer |
| Q35146660 | Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer. |
| Q35971034 | Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer |
| Q26823043 | Radiation dose effect in locally advanced non-small cell lung cancer |
| Q26765355 | Radio(chemo)therapy in locally advanced nonsmall cell lung cancer |
| Q42363788 | Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"? |
| Q35170255 | Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. |
| Q41988380 | Rare occurrence of cavitation of lung metastases following effective targeted therapy: A case report |
| Q46454623 | SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. |
| Q42848259 | SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. |
| Q59274268 | SEOM guidelines for the management of non-small-cell lung cancer (NSCLC) |
| Q38990822 | Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials |
| Q91630556 | Stage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort |
| Q38390036 | State of the art of radiotherapy. |
| Q38968702 | Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial |
| Q50088484 | Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest |
| Q29620596 | Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab |
| Q44991597 | Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial |
| Q41687834 | The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy |
| Q36823982 | The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. |
| Q101574526 | The cutting-edge progress of immune-checkpoint blockade in lung cancer |
| Q30239983 | The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis |
| Q36040638 | The importance of multidisciplinary team management of patients with non-small-cell lung cancer |
| Q38115503 | The role of consolidation treatment in locally advanced unresectable NSCLC. |
| Q36142491 | The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update |
| Q37642455 | Therapeutic management options for stage III non-small cell lung cancer |
| Q43240680 | Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy |
| Q39030907 | Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). |
| Q95295671 | Treatment guidance for lung cancer patients during the COVID-19 pandemic |
| Q37423919 | Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cance |
| Q36051895 | Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies |
| Q38930349 | Treatment: Radiation Therapy |
| Q41354382 | Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients? |
| Q84534783 | Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial |
| Q53199885 | Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoo |
| Q45122603 | Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer |
| Q86964709 | [Progression-free survival of patients with locally advanced NSCLC not improved by consolidation chemotherapy after concurrent chemoradiation] |
| Q87731116 | [The role of surgery for the management of resectable stage III non-small cell lung cancer] |
Search more.